Cantor Fitzgerald analyst Sarah James raised the firm’s price target on HCA Healthcare (HCA) to $525 from $444 and keeps an Overweight rating on the shares. HCA Heatlhcare’s operational excellence persists as it paves an achievable path to 2025 guidance and an optimistic 2026 outlook, the analyst tells investors in a research note. Preliminary 2026 commentary suggests fundamentals are well-intact, the firm adds.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target raised to $500 from $400 at Oppenheimer
- HCA Healthcare price target raised to $505 from $475 at Mizuho
- HCA Healthcare: Hold Rating Amid Limited Growth Potential and Policy Uncertainties
- HCA Healthcare price target raised to $475 from $465 at KeyBanc
- HCA Healthcare: Strong Financial Performance and Strategic Growth Drive Buy Rating